Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders

 Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders

Shots:

  • Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties, if Ipsen exercises its option
  • Exicure will be responsible for the discovery and pre-clinical development activities while Ipsen will lead further development and commercialization of the licensed product after exercising the option
  • Ipsen obtains exclusive options to license SNA based therapeutics for Huntington’s disease and Angelman syndrome based on two collaboration programs

Click here to  to read full press release/ article | Ref: Ipsen | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post